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Abstract 
Fungal endocarditis (FE) is a rare complica-
tion in immunocompromised patients which is
difficult to diagnose and has been character-
ized by excessive mortality (> 50%) and mor-
bidity, regardless of treatment. The lack of clin-
ical trials due to the small number of cases
contributes further to a poor outcome. In our
two  cases  of  aspergilllus  endocarditis  we
reviewed  the  clinical  features,  echocardio-
graphic  findings,  microbiologic  data,  treat-
ment, and outcome of these 2 cases and pro-
vide  a  current  characterization  of  the  syn-
drome. In this paper we have demonstrated the
diversity  of  presentation  of  a  critical  fungal
infection  in  immunocompromised  but  non
neutropenic  paediatric  patients.  The  prompt
diagnosis and initiation of treatment is crucial
for a favourable outcome along with the use of
double  antifungal  treatment  with  liposomal
amphotericin and voriconazole initially which
could  be  later  switched  to  oral  voriconazole
with  a  good  tissue  penetration.  Histological
samples as well as radiological evidence and
echocardiograms should be reviewed by expe-
rienced clinicians in order to aid diagnosis and
promptly initiate treatment for these patients
in order to achieve a favourable outcome
Introduction
Fungal endocarditis (FE) is an uncommon
occurrence. Previously published series report-
ed fungi as causes of infective endocarditis in
1.3-6% of cases. FE has been characterized by
excessive  mortality  (>50%)  and  morbidity,
regardless of treatment. A combined medical-
surgical approach seems to offer an improved
outcome. However, there are no clinical trials
to  support  or  refute  this  opinion,  largely
because of the rarity of the syndrome Advances
in medical and surgical therapies, including
reconstructive cardiovascular surgery, implan-
tation of intracardiac prosthetic devices, pro-
longed use of IV catheters, exposure to broad-
spectrum  antibiotics,  and  immunosuppres-
sion, have been implicated as causes of the
increase in the number of cases of fungemia
and FE seen. Establishing a definitive diagno-
sis  of  infective  endocarditis  is  frequently  a
problem.1,2 Aspergilli  are  widespread  molds
populating  virtually  every  site  of  organic
debris.  More  than  200  different  species  of
Aspergillus are known, but only a few are con-
sistently  pathogenic.  A.  fumigatus  and  A.
flavus  are  the  most  frequently  isolated
species.3
Case #1
A 2 years old girl was diagnosed with pre B-
ALL with a total white cell count of 43.000/dL
and started treatment on the UKALL2003 trial.
During  intensification  block  where  patients
receive Vincristine along with anthracyclines
she was admitted with ongoing pyrexia, tachy-
cardia, rigors and a blanching rash on the left
thigh.  The  full  blood  count  showed  a
WBC:3.000/dL N:1.800/dL and a high C-reactive
protein. As there was no obvious focus of infec-
tion and had a Hickman line she was started
on  broad  spectrum  antibiotics  for  presumed
line infection according to the regional proto-
col  (meropenem  and  vancomycin)  for
immunocompromised  patients  which  was
switched to second line antibiotics 48 hours
later due to persistent pyrexia. Simultaneously
blood  cultures  were  positive  for  aspergillus
fumigatus  .Clinical  examination  revealed  a
systolic  murmur  and  bilateral  crackles.  The
echocardiogram  demonstrated  a  right
atrium/Superior Vena Cava echogenic lesion
representing a vegetation. The biopsy of the
lesion confirmed the presence of aspergillus
fumigatus. The patient underwent a high reso-
lution chest CT scan which didn’t reveal any
evidence of fungal infection. Hickman line was
removed and a temporary neck line was insert-
ed  for  antifungal  treatment.  Chemotherapy
was withheld. She was commenced on liposo-
mal Amphotericin 3 mg/kg along with intra-
venous  voriconazole  which  was  switched  to
oral voriconazole once adequate levels in the
blood were reached. Liposomal amphotericin
was  discontinued  after  2  weeks  and  she
remained  on  oral  Voriconazole  throughout
chemotherapy. An Echocardiogram was repeat-
ed after 4 weeks and showed no evidence of
vegetations  with  negative  blood  cultures.
Currently the patient is well and in remission
from ALL
Case #2
An 11 years old boy diagnosed with Acute
Lymphoblastic leukaemia in March 2004. He
was treated on UKALL 2003 trial. During his
maintenance phase he was admitted to hospi-
tal with pyrexia and shortness of breath sug-
gestive  of  pneumonia.  The  full  blood  count
showed WBC:12000/dL N:8.400/dL and a high
C-reactive protein. Chest X-ray was normal. He
was  started  on  intravenous  meropenem  as
guided by the regional protocol for immuno-
compromised patients and four days later his
temperature was settled as well as his symp-
toms and in the absence of positive blood cul-
tures he was discharged from hospital on oral
clarithromycin.  However  5  days  later  the
patient was readmitted with pyrexia, produc-
tive cough and the chest X-ray showed right
middle lobe consolidation. He was started on
intravenous  cefuroxime  and  Azithromycin
with minimal improvement. Sputum samples
were  sent  for  microscopy  and  cultures.  Two
days later he developed a systolic murmur and
the  antibiotics  were  changed  to  benzylpeni-
cillin and gentamycin for presumed endocardi-
tis despite the lack of positive blood cultures.
In addition to this Aspergillus fumigatus was
grown  from  the  sputum  cultures.  He  had  a
high  resolution  CT  scan  of  the  chest  which
showed a cavitation on the right middle lobe
representing an aspergilloma. Treatment with
intravenous  Ambisome  was  initiated  along
with  intravenous  voriconazole  which  was
switched to the oral preparation 5 days later.
Unfortunately the patient developed profound
symptoms of cardiac failure and thus he had
an Echocardiogram which revealed a right ven-
tricular  outflow  tract  (RVOT)  vegetation  of
2.5¥2.0 cm. Due to the patient’s marked car-
diac  compromise  the  RVOT  vegetation  was
surgically resected and on the histopathologi-
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cal sections there were numerous PAS positive
hyphae representing Aspergillus. Cultures con-
firmed the presence of Aspergillus fumigatus.
Post operatively he became hypotensive and
required  inotropic  support  in  the  paediatric
intensive  care  unit.  Liposomal  Amphotericin
was  discontinued  after  17  days  and  he  was
continued  on  oral  voriconazole  for  three
months. He had a follow up high resolution CT
scan and an ECHO which confirmed complete
resolution of the aspergillomas.
Discussion
Systemic  aspergillus  endocarditis  occurs
mainly  in  severely  immunocompromised
patients and in most cases in the literature
includes a pulmonary focus and the survival
was frequently poor.4 Review of the British lit-
erature showed five patients with fungal endo-
carditis in the setting of bone marrow trans-
plantation and revealed the same difficulties
in  diagnosis  and  poor  outcome.5,6
Amphotericin B, as exemplified in the current
literature  review,  remains  the  mainstay  of
medical  therapy.  Mortality  caused  by
Aspergillus  endocarditis  in  recent  literature
reviews is around 80%, and surgical interven-
tion with valve replacement did not improve
mortality  rates  as  compared  with  rates  for
patients who received antifungal  monothera-
py  with  Amphotericin  B.7,8 In  our  first  case
liposomal Amphotericin B along with voricona-
zole resolved the aspergillus endocarditis in a
month without the need for surgical interven-
tion whereas on the second case due to the
cardiocirculatory  compromise  ,urgent  resec-
tion of the aspergilloma along with combined
antifungal therapy was indicated and despite
the need for intensive care treatment the out-
come was good. In the literature a patient with
prosthetic  valve  endocarditis  due  to
Aspergillus fumigatus was successfully treated
with aggressive surgical debridement alone.9
The  rarity  of  the  syndrome  coupled  with
negative  blood  culture  results  in  most  mold
cases and some yeast cases compromises our
ability to secure an early diagnosis.10 However
in our cases Aspergillus fumigatus was isolat-
ed from the blood cultures in our first case
which was found very rarely in the internation-
al literature and from the sputum cultures in
our second case enabling us to initiate treat-
ment promptly. Furthermore the large vegeta-
tions  that  characterize  this  illness  seem  to
increase  the  sensitivity  of  transthoracic
echocardiogram and should prompt a consider-
ation of fungal endocarditis in the setting of
blood  culture-negative  endocarditis  in  the
immunocompromised patient.11
The lack of pulmonary involvement in our
first case in the presence of generalized infec-
tion  with  Aspergillus  fumigatus  is  unique,
since most of the cases reported to date includ-
ed severe pulmonary disease. Despite the lack
of  clinical  and  pathological  signs  of  a  pul-
monary  port  of  entry,  infection  through  the
respiratory tract cannot be ruled out, since the
respiratory tract is considered the usual port of
entry for these organisms although the pres-
ence of the central line in our first case favours
its use as the main site for Aspergillus entry
and hence it was removed rapidly. In our sec-
ond case, no venous access device had been in
place during the onset of fever, and preceding
bacterial sepsis with pneumonia might have
caused pulmonary tissue damage, facilitating
aspergillus entry along with the use of broad
spectrum antibiotics. According to the interna-
tional literature the strongest risk factor for
disseminated aspergillosis is prolonged granu-
locytopenia in the context of immunosuppres-
sive chemotherapy. In our patients aspergillus
endocarditis presented in complete remission
from leukemia, and the neutrophil count was
normal at the onset of infection.12
In conclusion these two cases of Aspergillus
endocarditis showed the diversity of presenta-
tion of a critical fungal infection in immuno-
compromised  non  neutropenic  paediatric
patients. The prompt diagnosis and initiation
of treatment is crucial for a favourable out-
come along with the use of double antifungal
treatment  with  liposomal  amphotericin  and
voriconaz which could be later switched to oral
voriconazole with a good tissue penetration. 
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